Docstoc

Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development

Document Sample
Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development Powered By Docstoc
					Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology
Pipeline Leads with Most Promising Molecules in Late Stage Development

Oncology, Metabolic Disorders and CNS Command Robust Late Stage Pipeline

The therapy areas that command the largest number of molecules in the late stage
pipeline are – oncology, metabolic disorders and central nervous system disorders.
Oncology accounts for the majority of pipeline activity, with 37% of the entire pipeline.
The focus on oncology to develop novel anti-cancer drugs is driven partly by patients’
constant need to switch treatments due to the side effects of heavy chemotherapy. Several
companies, including Pfizer, Sanofi-aventis, Bristol-Myers Squibb (BMS) and Amgen
are developing protein-based therapeutics since they do not carry the adverse effects
associated with intense chemotherapy.

Tyrosine kinase inhibitors are one of the most prominent developing classes of drug
undergoing Phase II and Phase III evaluation; they account for approximately 40% of the
Phase III promising molecules in oncology, followed by therapeutic vaccines,
mammalian target of rapamycin (mTOR) inhibitors and Cytochrome P450 inhibitors
among others. Specific inhibitors of tyrosine kinases are extremely advantageous and
provide more promise against monoclonal antibodies since they are targeted at the
tyrosine kinase activity of receptor tyrosine kinase (RTK). Inhibition of the activity of
receptor and other tyrosine kinases represents a rational strategy to stop the functions of
cells that rely on these pathways for survival. Non-cancer applications of kinase
inhibitors are seen across diseases such as autoimmune diseases, restenosis, diabetes and
other disorders.

For Sample Pages, please click or add the below link to your browser:
http://gbiresearch.com/RequestSamplePages.aspx?ID=Comparative-Analysis-of-Late-
Stage-Pipeline-Molecules-in-Major-Indications-Oncology-Pipeline-Leads-with-Most-
Promising-Molecules-in-Late-Stage-
Development&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&
CompanyID=dcsto

Type 2 diabetes has the highest number of me-too drugs among all the indications
analyzed with 174 such products in the pipeline accounting for 69% of the entire
pipeline. Me-too drugs largely duplicate the action of existing drugs and diminish the
incentives for innovation in pioneering drugs without adding therapeutic value. However,
the more differentiated me-too drugs are from pioneering drugs, the greater their potential
benefits. In the case of type 2 diabetes, these me-too drugs are anticipated to provide
better efficacy and safety profiles. Several glitazones and glucagon-like peptide-1 (GLP-
1) analogues are me-too drugs in the pipeline.


GBI Research, the leading business intelligence provider, has released its latest research
“Comparative Analysis of Late Stage Pipeline Molecules in Major Indications –
Oncology Pipeline Leads the Most Promising Molecules in Late Stage Development”. It
provides a comprehensive analysis of the late stage pipeline molecules in 14 key
indications from nine major therapy areas. The report provides in-depth coverage of the
pipeline activity in the major indications, giving a wide view on the changing focus of the
therapeutic landscape. Each chapter deals exhaustively with one indication, giving: an
overview of the opportunity and unmet need in the market; a strategic pipeline
assessment that covered the distribution of the pipeline according to their mechanism of
action and class of drug, whether first-in-class, me-too, or generic or product extension;
and a comparative analysis of key late stage pipeline molecules based on the major
characteristics of targeted unmet need, mechanism of action, efficacy and safety.
Furthermore, the report provides profiles of the promising drugs under clinical
development.

This report is built using data and information sourced from proprietary databases,
primary and secondary research and in-house analysis by GBI Research’s team of
industry experts.

For further details, please click or add the below link to your browser:
http://gbiresearch.com/Report.aspx?ID=Comparative-Analysis-of-Late-Stage-Pipeline-
Molecules-in-Major-Indications-Oncology-Pipeline-Leads-with-Most-Promising-
Molecules-in-Late-Stage-
Development&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceutical
s_and_Healthcare&CompanyID=dcsto

Visit our report store: http://www.gbiresearch.com

For more details contact:
pressreleases@gbiresearch.com
North America:        +1 646 395 5477
Europe:               +44 207 753 4299
                      +44 1204 543 533
Asia Pacific:         +91 40 6616 6782

				
DOCUMENT INFO
Shared By:
Stats:
views:14
posted:7/7/2011
language:English
pages:2
Description: Oncology, Metabolic Disorders and CNS Command Robust Late Stage Pipeline